# TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

> **NCT02493530** · PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Myelofibrosis
- Polycythemia Vera

## Interventions

- **DRUG:** TGR-1202
- **DRUG:** ruxolitinib

## Key facts

- **NCT ID:** NCT02493530
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2023-03-21
- **Final completion:** 2024-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493530, "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02493530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*